Detalles de la búsqueda
1.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Am Heart J;
267: 1-11, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37758044
2.
Incretin hormones and type 2 diabetes.
Diabetologia;
66(10): 1780-1795, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37430117
3.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Circulation;
145(8): 575-585, 2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34903039
4.
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
Cardiovasc Diabetol;
22(1): 153, 2023 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37381019
5.
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
Cardiovasc Diabetol;
22(1): 59, 2023 03 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36927451
6.
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Diabetes Obes Metab;
25(5): 1361-1371, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36700380
7.
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Cardiovasc Diabetol;
21(1): 169, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36050763
8.
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
Cardiovasc Diabetol;
21(1): 50, 2022 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35395808
9.
Consensus report: Definition and interpretation of remission in type 2 diabetes.
Diabet Med;
39(3): e14669, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34460965
10.
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment.
Diabetes Obes Metab;
24(5): 806-815, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34984794
11.
Consensus report: definition and interpretation of remission in type 2 diabetes.
Diabetologia;
64(11): 2359-2366, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34458934
12.
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Diabetes Obes Metab;
23 Suppl 3: 5-29, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310013
13.
Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.
Diabetes Obes Metab;
23(10): 2344-2353, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34189834
14.
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Lancet;
394(10192): 39-50, 2019 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31186120
15.
Report from the 5th cardiovascular outcome trial (CVOT) summit.
Cardiovasc Diabetol;
19(1): 47, 2020 04 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-32303223
16.
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Diabetes Obes Metab;
22(4): 699-704, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31750601
17.
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
Diabetes Obes Metab;
22(4): 599-611, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31793165
18.
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials.
Diabetes Obes Metab;
22(9): 1537-1547, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32314525
19.
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Diabetes Obes Metab;
22(10): 1886-1891, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32519795
20.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Diabetes Obes Metab;
22(6): 938-946, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31984598